Kopran Investor Presentation: Key Takeaways
Kopran Q2 FY27 consolidated revenue ₹21,126 Lakh (+79% YoY), EBITDA ₹1,822 Lakh (8.62%), PAT ₹439 Lakh vs prior-year loss; borrowings up.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Kopran Q2 FY27 consolidated revenue ₹21,126 Lakh (+79% YoY), EBITDA ₹1,822 Lakh (8.62%), PAT ₹439 Lakh vs prior-year loss; borrowings up.
Kopran Ltd reported revenue from operations of ₹211.3 Cr (+79.2% YoY) and net profit of ₹4.4 Cr for Q2 FY27.
Kopran Ltd intimates a board meeting on November 3, 2026, to consider and approve Q2 FY27 unaudited financial results. No financial figures are disclosed in this advance notice.
Kopran's Khopoli formulation facility concluded an EU GMP inspection with no critical or data-integrity observations. The company will submit compliance responses for one major and minor findings within two weeks.
Kopran Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Sarvamangal Mercantile Company Limited acquired 170,000 shares of Kopran Ltd through market purchases. The transaction increases the promoter group's stake in the target company by 0.35%.
Kopran Limited responded to NSE's price-movement query stating no material information was withheld. The stock's rise is attributed to purely market-driven forces.
Kopran Limited allotted 40,500 equity shares to employees under its ESOP 2023 scheme. The exercise price for these shares is Rs 179 per share.